Over 36 months, tirzepatide lowered body weight and blood sugar levels more than dulaglutide in adults with type 2 diabetes and heart disease, while both drugs had similar effects on cardiovascular...
Mechanism
Synthesis from 1 study
Tirzepatide works better than dulaglutide because it turns on two signals in the body that help make insulin and tell your brain you're full. This means you eat less, lose more weight, and your blood sugar stays lower. Dulaglutide only turns on one of those signals, so it doesn't work as well.
Most probable mechanism
Tirzepatide activates two different receptors in the body that help the pancreas release more insulin when blood sugar is high, stop the liver from releasing too much sugar, and signal the brain to feel full sooner. This means less food is eaten, weight goes down, and blood sugar stays lower for longer.
Tirzepatide binds to and activates GLP-1 and GIP receptors on pancreatic beta cells
Receptor activation increases glucose-dependent insulin secretion and suppresses glucagon release
Improved glycemic control reduces chronic hyperglycemia and associated oxidative stress
Activation of GLP-1 and GIP receptors in the hypothalamus and adipose tissue reduces appetite and increases satiety
Reduced caloric intake leads to loss of adipose tissue, particularly visceral fat
Decreased adipose tissue mass reduces systemic inflammation and improves insulin sensitivity in liver and muscle
Lower insulin resistance and sustained insulin secretion maintain reduced blood glucose levels
Evidence from Studies
Supporting (1)
Community contributions welcome
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.